Log in to save to my catalogue

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendoc...

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendoc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11753395

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors

About this item

Full title

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors

Publisher

US: Oxford University Press

Journal title

The oncologist (Dayton, Ohio), 2025-01, Vol.30 (1)

Language

English

Formats

Publication information

Publisher

US: Oxford University Press

More information

Scope and Contents

Contents

Abstract
Objectives
Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with soma...

Alternative Titles

Full title

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11753395

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11753395

Other Identifiers

ISSN

1083-7159,1549-490X

E-ISSN

1549-490X

DOI

10.1093/oncolo/oyae364

How to access this item